MicroRNA in Human Malignancies offers a deep overview of the role and translational significance of miRNAs in the development of cancer and other malignancies. The book establishes the foundations of the field by covering essential mechanisms and the translational potential of miRNAs in the field of oncology. Specific topics covered include invasion and metastasis, miRNAs and metabolism, and opportunities of miRNAs in therapeutics. Chapters on diseases include content on disease-related pathophysiology, as well as diagnostic, prognostic and predictive value. This book is an essential reference for students entering the field, as well as researchers and investigators.

Being diagnosed with incurable cancer that had spread to the liver and bones, might justifiably be regarded as a bad day at the oncologist's office. Add to this a fractured neck, a life expectancy of six months and isolation from loved ones due to Covid lockdowns, and one could be forgiven for descending into the depth of despair. But not Issy Hogg. On receiving the news, this indefatigable and fun-loving defence lawyer told her oncologist, in true Shakespearean style, that she had no intention of 'shuffling off this mortal coil' anytime soon. Issy then began regaling family and friends with a series of amusing and inspirational posts providing updates on her experience in hospital, treatment programme and anecdotes from an eventful professional and personal life. Over a year beyond her death sentence, Issy has committed her experiences to this book. The primary aim being to share the overwhelming benefits of positive thought and a, literary, 'never say die' approach with those who encounter or fear unwelcome life-changing events of whatever nature.

"Alison, I’ve got bad news."

The voice of the pathologist at the other end of the telephone confirmed for Alison Tucker the news no woman ever wants to hear: she had breast cancer. Once the shock had settled, Alison decided that she would take charge. Not only would she take ownership of the dreaded disease, but she would do so with a positive mindset and prepare herself as best she could for what was to come. She did detailed research and paid close heed to what she was told by others who had walked the path before her. As she navigated her way through surgery and the chemotherapy and radiotherapy that followed, Alison’s determination paid off. Not only did she make new friends, but she learnt valuable life lessons too: acceptance of the illness for what it was, the amazing impact of ongoing advances in medical science, and the importance of being able to ask for – and receive – help.

In My Best Worst Year – A Breast Cancer Story, Alison gives us an authentic account of her experience, offering insights and advice for others who might one day face the same diagnosis. You will accompany her on her highs, empathise with her lows, and be amused by humorous anecdotes along the way. Through the generous support of family and friends, she has amassed a collection of practical tips for both patients and supporters which she shares with open-hearted honesty:

• What to take to chemotherapy sessions
• What to look for when choosing a wig
• What side effects a person can expect when having the various types of cancer treatment
• What to say, and what not to say, to a cancer patient
• How to remove stress from a cancer patient’s life
• What kind of gifts and gestures are most appreciated

Contrary to Alison’s expectations, her year of treatment turned out to be her best worst year. By telling her story, she underlines the importance of a positive attitude and hopes to show that a person can still lead a productive and enjoyable life even after being diagnosed with cancer.

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies takes a look at the current strategies, successes and challenges involved with the development of novel formulations of biologics, vaccines and cancer therapy. This thorough reference on the latest trends in the development of diverse modalities will appeal to a broad community of scientists, students and clinicians. Written by leading authors across academia and industry, this book covers important topics such as unique drug delivery devices, non-parenteral delivery trends, novel approaches to the treatment of cancer, immunotherapy and more. It includes real-world cases and examples which highlight formulations with therapeutic proteins, monoclonal antibodies, peptides and biobetters, as well as cases on novel vaccines formulations including evolving pathogens, novel modalities of vaccines, universal vaccines. This book is a thorough and useful resource on the development of novel biologics, vaccines and cancer therapies.

This is a comprehensive guide to the science, diagnosis and treatment of craniopharyngiomas, rare brain tumors that grow near the pituitary gland. Even though these tumors are generally benign, due to the location, prognosis was often bleak. New diagnostic, imaging and surgical techniques, including endoscopic endonasal cranial base surgery, now enable successful neurosurgical intervention. With a better prognosis, patients require multidisciplinary management from neurology, otolaryngology, radiation oncology, endocrinology, and neuropathology. This reference will provide a resource for these specialists requiring a comprehensive overview of this rare form of tumor.

*The only comprehensive guide to the science, diagnosis and treatment of craniopharyngiomas

*Includes multidisciplinary management from neurology, otolaryngology, radiation oncology, endocrinology, and neuropathology

*Detailed coverage of the impacts of new diagnostic, imaging and neurosurgical techniques including endoscopic endonasal cranial base surgery

With an annual rate of more than 12 million global diagnoses and 7.6 million deaths, the societal and economic burden of cancer cannot be overstated. Brain metastases are the most common malignant tumors of the central nervous system, yet their incidence appears to be increasing in spite of the advancement of cancer therapies. While much is known about primary cancers (including primary brain tumors), less work has been done to uncover the roots of metastatic disease. This series fills that gap, serving as the first two part reference to focus primarily on the link between primary cancers and brain metastases. This link is explored for the most common cancer types - lung, breast, and melanoma. Additionally, biological background as well as therapy for CNS metastases is addressed. Age and gender related trends are also discussed, as is the use of biomarkers for early detection.

* The only comprehensive reference detailing the link between primary cancers and brain metastases

* Aids the target audience in determining the incidence of brain metastases in patients with a primary cancer

* Provided education about the potential use of biomarkers for early detection, diagnosis and prevention of the spread of primary cancer to the brain

* Documents temporal and gender-related trends in brain metastases from other cancers

* Edited work with chapters authored by leaders in the field around the globe - the broadest, most expert coverage available

The interactions of cells with their surrounding extracellular matrix (ECM) plays a pivotal role in driving normal cell behavior, from development to tissue differentiation and function. At the cellular level, organ homeostasis depends on a productive communication between cells and ECM, which eventually leads to the normal phenotypic repertoire that characterize each cell type in the organism. A failure to establish these normal interactions and to interpret the cues emanating from the ECM is one of the major causes in abnormal development and the pathogenesis of multiple diseases. To recognize and act upon the biophysical signals that are generated by the cross talk between cells and ECM, the cells developed specific receptors, among them a unique set of receptor tyrosine kinases (RTKs), known as the Discoidin Domain Receptors (DDRs). The DDRs are the only RTKs that specifically bind to and are activated by collagen, a major protein component of the ECM. Hence, the DDRs are part of the signaling networks that translate information from the ECM, and thus they are key regulators of cell-matrix interactions. Under physiological conditions, DDRs control cell and tissue homeostasis by acting on collagen sensors; transducing signals that regulate cell polarity, tissue morphogenesis, cell differentiation, and collagen deposition. DDRs play a key role in diseases that are characterized by dysfunction of the stromal component, which lead to abnormal collagen deposition and the resulting fibrotic response that disrupt normal organ function in disease of the cardiovascular system, lungs and kidneys, just to mention a few. In cancer, DDRs are hijacked by tumor and stromal cells to disrupt normal cell-collagen communication and initiate pro-oncogenic programs. Importantly, several cancer types exhibit DDR mutations, which are thought to alter receptor function, and contribute to cancer progression. Therefore, the strong causative association between altered RTK function and disease it is been translated today in the development of specific tyrosine kinase inhibitors targeting DDRs for various disease conditions. In spite of the accumulating evidence highlighting the importance of DDRs in health and diseases, there is still much to learn about these unique RTKs, as of today there is a lack in the medical literature of a book dedicated solely to DDRs. This is the first comprehensive volume dedicated to DDRs, which will fill a gap in the field and serve those interested in the scientific community to learn more about these important receptors in health and disease.

Anti-angiogenic Drugs as Chemosensitizers in Cancer Therapy, Volume 19 focuses on the use of anti-angiogenic drugs as sensitizers of tumor cells to the inhibitory activity of antitumor agents. Conventional and novel anti-neoplastic agents (cytotoxic molecules, hormones/antihormones, immunotherapies) are taken into consideration, along with advances made in combination therapies. The book encompasses examples of studies on the use of antiangiogenic compounds-molecules that inhibit the growth of vessels inside a tumor-together with antineoplastic drugs in order to sensitize the resistant tumor to their cytotoxic effects, thus reducing adverse side reactions and resistance and improving the therapeutic response of cancer patients. In addition, the book discusses clinical applications in various types of cancer, such as colorectal, lung, breast, renal, genitourinary, skin and brain and circulating tumors. It is a valuable resource for cancer researchers, clinicians and members of the biomedical field who wants to be up-to-date on the most recent and promising developments in the field.

Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations. A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed. This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes.

Bone Cancer, Second Edition comprehensively investigates key discoveries in the field of bone biology over the last five years that have led to the development of entirely new areas for investigation, such as therapies which combine surgery and biological approaches. The Second Edition expands on the original overview of bone cancer development (physiology and pathophysiology), with key chapters from the first edition, and offers numerous new chapters describing the new concepts of bone cancer biology and therapy, for both primary bone tumors as well as bone metastases. Each chapter has been written by internationally recognized specialists on the bone cancer microenvironment, bone metastases, osteoclast biology in bone cancer, proteomics, bone niche, circulating tumor cells, and clinical trials. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for everyone within the medical and cancer research communities. Bone Cancer continues to offer the only translational reference to cover all aspects of primary bone cancer and bone metastases - from bench to bedside: development (cellular and molecular mechanisms), genomic and proteomic analyses, clinical analyses (histopathology, imaging, pain monitoring), as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics Volume 122 explores subjects related to redox, including: redox homeostasis in epithelial-derived cancers; reactive oxygen species in normal and tumor stem cells; and gamma-glutamyl transpeptidase and redox regulation.
Provides information on cancer researchOutstanding and original reviewsSuitable for researchers and students"

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.
Provides information on cancer researchOutstanding and original reviewsSuitable for researchers and students

Volume 542 of "Methods in Enzymology" continues the legacy of this premier serial with quality chapters authored by leaders in the field. This new volume covers research methods providing a theoretical overview on metabolic alterations of cancer cells and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo. Malignant cells exhibit metabolic changes when compared to their normal counterparts, owing to both genetic and epigenetic alterations. Although such a metabolic rewiring has recently been indicated as "yet another" general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm rather represent a molecular signature that intimately accompanies, and hence cannot be severed from, all facets of malignant transformation.
Continues the legacy of this premier serial with quality chapters authored by leaders in the field Covers research methods in biomineralization scienceProvides theoretical overview on metabolic alterations of cancer cells, and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo

The traditional approach to cancer is that the patient must view cancer as the enemy and engage in a war to vanquish that enemy. Ann Wax, RN, argues that this approach is incorrect and invariably leads to pain, self doubt, and depression. Instead, she argues that one must find calm and inner-peace first, in order to promote healing.

Despite success with treatment when diagnosed early, breast cancer is still one of the most fatal forms of cancer for women. Imaging diagnosis is still one of the most efficient ways to detect early breast changes with mammography among the most used techniques. However, there are other techniques that have emerged as alternatives or even complementary tests in the early detection of breast lesions (e.g., breast thermography and electrical impedance tomography). Artificial intelligence can be used to optimize image diagnosis, increasing the reliability of the reports and supporting professionals who do not have enough knowledge or experience to make good diagnoses. Biomedical Computing for Breast Cancer Detection and Diagnosis is a collection of research that presents a review of the physiology and anatomy of the breast; the dynamics of breast cancer; principles of pattern recognition, artificial neural networks, and computer graphics; and the breast imaging techniques and computational methods to support and optimize the diagnosis. While highlighting topics including mammograms, thermographic imaging, and intelligent systems, this book is ideally designed for medical oncologists, surgeons, biomedical engineers, medical imaging professionals, cancer researchers, academicians, and students in medicine, biomedicine, biomedical engineering, and computer science.

"Molecular Diagnostics andTreatment of Pancreatic Cancer "describes the different emerging applications of systems biology and howit is shaping modern pancreatic cancer research. This book begins by introducing the current state of the art knowledge, trends in diagnostics, progress in disease model systems as well as new treatment and palliative care strategies in pancreatic cancer. Specific sections are dedicated to enlighten the readers to newer discoveries that have emerged from gene expression profiling, proteomics, metabolomics and systems level analyses of pancreatic cancer datasets. First of a kind and novel network strategies to understand oncogenic Kras signaling in pancreatic tumors are presented. The attempts to computationally model and prioritize microRNAs that cause pancreatic cancer resistance are alsohighlighted.

Addressing this important area, "Molecular Diagnostics and Treatment of Pancreatic Cancer" provides insights into important network evaluation methodologies related to pancreatic cancer related microRNAs targetome. There are dedicated chapters on critical aspects of the evolving yet controversial field of pancreatic cancer stems cells. The work concludes by discussing the applications of network sciences in pancreatic cancer drug discovery and clinical trial design.
Encompasses discussion of innovative tools including expression signatures in cell lines, 3D models, animal xenograft models, primary models and patient derived samples, aiding subversion of traditional biology paradigms, and enhancing comprehension across conventional length and temporal scalesCoverage includes novel applications in targeted drugs, polypharmacology, network pharmacology and other related drug development arenas - helping researchers in pancreatic cancer drug discoverySummarizes many relevant computational and clinical references from fast-evolving literatureComprehensive glossary helps newer readers understand technical terms and specialized nomenclature"

Aiding researchers seeking to eliminate multi-step procedures, reduce delays in treatment and ease patient care, "Cancer Theranostics" reviews, assesses, and makes pertinent clinical recommendations on the integration of comprehensive in vitro diagnostics, in vivo molecular imaging, and individualized treatments towards the personalization of cancer treatment.

"Cancer Theranostics" describes the identification of novel biomarkers to advance molecular diagnostics of cancer. The book encompasses new molecular imaging probes and techniques for early detection of cancer, and describes molecular imaging-guided cancer therapy. Discussion also includes nanoplatforms incorporating both cancer imaging and therapeutic components, as well as clinical translation and future perspectives.
Supports elimination of multi-step approaches and reduces delays in treatments through combinatorial diagnosis and therapyFully assesses cancer theranostics across the emergent field, with discussion of biomarkers, molecular imaging, imaging guided therapy, nanotechnology, and personalized medicine Content bridges laboratory, clinic, and biotechnology industries to advance biomedical science and improve patient management

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers.